A kind of medicine for treating dilated cardiomyopathy and its screening and preparation method

A dilated cardiomyopathy and drug technology, applied in biochemical equipment and methods, pharmaceutical formulations, drug combinations, etc., can solve the problem that is poorly understood, the relationship between viral miRNAs and dilated cardiomyopathy has not been reported, and there is no viral miRNAs treatment Drug and other problems, to achieve the effects of easy detection, improvement of the connection function between vascular endothelial cells, and overcoming the problem of drug resistance
CN109706241BActive Publication Date: 2020-09-25TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Publication Date
2020-09-25

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a medicine for treating dilated cardiomyopathy as well as a screening and preparation method thereof, which belong to the field of medical bioengineering. The medicinal component of the medicine comprises kshv-miR-K12-1-5p as a drug target, the substance of the kshv-miR-K12-1-5p is subjected to binding, degrading, and / or down-regulated expression. The medicine takes kshv-miR-K12-1-5p as a drug target, can significantly improve the intercellular junctional dysfunction caused by KSHV infection and damage due to barrier action by down-regulated expression of kshv-miR-K12-1-5p molecules, and potentially improves the function of the heart.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to a drug for treating dilated cardiomyopathy and its screening and preparation methods, in particular to a new medical application of an antisense complementary sequence of acquired viral non-coding small RNA, more specifically to a The use of non-coding kshv-miR-K12-1-5p antisense complementary sequence in the treatment of dilated cardiomyopathy and the screening and preparation method of drugs containing the non-coding kshv-miR-K12-1-5p antisense complementary sequence, It belongs to the field of medical bioengineering. Background technique

[0002] Chronic dilated cardiomyopathy is a clinical syndrome that develops to the end stage of different cardiovascular diseases. The main pathophysiological features are impaired ventricular filling and ejection ability, which eventually leads to low ventricular pumping function. It has a poor prognosis and high mortality. , is one of the most important causes that threaten human...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More